Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Micron Technology, Inc. Reports Results for the First Quarter of Fiscal 2022

Published

2 years ago

on

BOISE, Idaho, Dec. 20, 2021 (GLOBE NEWSWIRE) — Micron Technology, Inc. (Nasdaq: MU) today announced results for its first quarter of fiscal 2022, which ended Dec. 2, 2021.

Fiscal Q1 2022 highlights

  • Revenue of $7.69 billion versus $8.27 billion for the prior quarter and $5.77 billion for the same period last year
  • GAAP net income of $2.31 billion, or $2.04 per diluted share
  • Non-GAAP net income of $2.47 billion, or $2.16 per diluted share
  • Operating cash flow of $3.94 billion versus $3.88 billion for the prior quarter and $1.97 billion for the same period last year

“Micron delivered solid fiscal first quarter results led by strong product portfolio momentum,” said Micron Technology President and CEO Sanjay Mehrotra. “We are now shipping our industry-leading DRAM and NAND technologies across major end markets, and we delivered new solutions to data center, client, mobile, graphics and automotive customers. As powerful secular trends including 5G, AI, and EV adoption fuel demand growth, our technology leadership and world-class execution position us to create significant shareholder value in fiscal 2022 and beyond.”

Quarterly Financial Results
(in millions, except per share amounts) GAAP(1)   Non-GAAP(2)
FQ1-22 FQ4-21 FQ1-21   FQ1-22 FQ4-21 FQ1-21
               
Revenue $ 7,687   $ 8,274   $ 5,773     $ 7,687   $ 8,274   $ 5,773  
Gross margin 3,565   3,912   1,736     3,616   3,964   1,784  
percent of revenue 46.4 % 47.3 % 30.1 %   47.0 % 47.9 % 30.9 %
Operating expenses 934   957   870     891   891   811  
Operating income 2,631   2,955   866     2,725   3,073   973  
percent of revenue 34.2 % 35.7 % 15.0 %   35.4 % 37.1 % 16.9 %
Net income 2,306   2,720   803     2,471   2,778   897  
Diluted earnings per share 2.04   2.39   0.71     2.16   2.42   0.78  

Investments in capital expenditures, net(2) were $3.27 billion for the first quarter of 2022, which resulted in adjusted free cash flows(2) of $671 million. Micron repurchased approximately 3.6 million shares of its common stock for $259 million during the first quarter of fiscal 2022 and ended the quarter with cash, marketable investments, and restricted cash of $11.48 billion, for a net cash(2) position of $4.46 billion.

On December 17, 2021, Micron’s Board of Directors declared a quarterly dividend of $0.10 per share, payable in cash on January 18, 2022, to shareholders of record as of the close of business on January 3, 2022.

Business Outlook

The following table presents Micron’s guidance for the second quarter of 2022:

FQ2-22 GAAP(1) Outlook Non-GAAP(2) Outlook
     
Revenue $7.5 billion ± $200 million $7.5 billion ± $200 million
Gross margin 45.0% ± 1% 46.0% ± 1%
Operating expenses $1,058 million ± $25 million $975 million ± $25 million
Diluted earnings per share $1.83 ± $0.10 $1.95 ± $0.10

Further information regarding Micron’s business outlook is included in the prepared remarks and slides, which have been posted at investors.micron.com.

Investor Webcast

Micron will host a conference call on Monday, Dec. 20, 2021 at 2:30 p.m. MT to discuss its first quarter financial results and provide forward-looking guidance for its second quarter. A live webcast of the call will be available online at investors.micron.com. A webcast replay will be available for one year after the call. For Investor Relations and other company updates, follow @MicronTech on Twitter at twitter.com/MicronTech.

About Micron Technology, Inc.

We are an industry leader in innovative memory and storage solutions transforming how the world uses information to enrich life for all. With a relentless focus on our customers, technology leadership, and manufacturing and operational excellence, Micron delivers a rich portfolio of high-performance DRAM, NAND, and NOR memory and storage products through our Micron® and Crucial® brands. Every day, the innovations that our people create fuel the data economy, enabling advances in artificial intelligence and 5G applications that unleash opportunities — from the data center to the intelligent edge and across the client and mobile user experience. To learn more about Micron Technology, Inc. (Nasdaq: MU), visit micron.com.

© 2021 Micron Technology, Inc. All rights reserved. Micron, the Micron logo, and all other Micron trademarks are the property of Micron Technology, Inc. All other trademarks are the property of their respective owners.

Forward-Looking Statements

This press release contains forward-looking statements regarding our industry, our strategic position, and our financial and operating results. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially. Please refer to the documents we file with the Securities and Exchange Commission, specifically our most recent Form 10-K. These documents contain and identify important factors that could cause our actual results to differ materially from those contained in these forward-looking statements. These certain factors can be found at www.micron.com/certainfactors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. We are under no duty to update any of the forward-looking statements after the date of this release to conform these statements to actual results.

(1)   GAAP represents U.S. Generally Accepted Accounting Principles.
(2)   Non-GAAP represents GAAP excluding the impact of certain activities, which management excludes in analyzing our operating results and understanding trends in our earnings, adjusted free cash flow, net cash, and business outlook. Further information regarding Micron’s use of non-GAAP measures and reconciliations between GAAP and non-GAAP measures are included within this press release.

 
 
MICRON TECHNOLOGY, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In millions, except per share amounts)
(Unaudited)
 
  1st Qtr. 4th Qtr. 1st Qtr.
  December 2,
2021		 September 2,
2021		 December 3,
2020
       
Revenue $ 7,687     $ 8,274     $ 5,773  
Cost of goods sold 4,122     4,362     4,037  
Gross margin 3,565     3,912     1,736  
       
Research and development 712     705     647  
Selling, general, and administrative 259     236     214  
Restructure and asset impairments 38     22     8  
Other operating (income) expense, net (75 )   (6 )   1  
Operating income 2,631     2,955     866  
       
Interest income 10     9     10  
Interest expense (45 )   (47 )   (48 )
Other non-operating income (expense), net (75 )   19     13  
  2,521     2,936     841  
       
Income tax (provision) benefit (219 )   (230 )   (51 )
Equity in net income (loss) of equity method investees 4     14     13  
Net income $ 2,306     $ 2,720     $ 803  
       
Earnings per share      
Basic $ 2.06     $ 2.42     $ 0.72  
Diluted 2.04     2.39     0.71  
       
Number of shares used in per share calculations      
Basic 1,119     1,123     1,115  
Diluted 1,130     1,138     1,135  
                 
                 

MICRON TECHNOLOGY, INC.
CONSOLIDATED BALANCE SHEETS
(In millions)
(Unaudited)

As of December 2,
2021		 September 2,
2021
     
Assets    
Cash and equivalents $ 8,680   $ 7,763  
Short-term investments 900   870  
Receivables 5,250   5,311  
Inventories 4,827   4,487  
Assets held for sale 13   974  
Other current assets 521   502  
Total current assets 20,191   19,907  
Long-term marketable investments 1,817   1,765  
Property, plant, and equipment 35,155   33,213  
Operating lease right-of-use assets 574   551  
Intangible assets 347   349  
Deferred tax assets 746   782  
Goodwill 1,228   1,228  
Other noncurrent assets 1,188   1,054  
Total assets $ 61,246   $ 58,849  
     
Liabilities and equity    
Accounts payable and accrued expenses $ 5,470   $ 5,325  
Current debt 118   155  
Other current liabilities 924   944  
Total current liabilities 6,512   6,424  
Long-term debt 6,904   6,621  
Noncurrent operating lease liabilities 523   504  
Noncurrent unearned government incentives 767   808  
Other noncurrent liabilities 632   559  
Total liabilities 15,338   14,916  
     
Commitments and contingencies    
     
Shareholders’ equity    
Common stock 122   122  
Additional capital 9,564   9,453  
Retained earnings 41,267   39,051  
Treasury stock (4,954 ) (4,695 )
Accumulated other comprehensive income (loss) (91 ) 2  
Total equity 45,908   43,933  
Total liabilities and equity $ 61,246   $ 58,849  
     
     

MICRON TECHNOLOGY, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
(Unaudited)

Three months ended December 2,
2021		 December 3,
2020
     
Cash flows from operating activities    
Net income $ 2,306   $ 803  
Adjustments to reconcile net income to net cash provided by operating activities    
Depreciation expense and amortization of intangible assets 1,671   1,487  
Stock-based compensation 118   92  
(Gain) loss on debt repurchases and conversions 83   —  
Change in operating assets and liabilities    
Receivables 67   251  
Inventories (344 ) 130  
Accounts payable and accrued expenses (42 ) (753 )
Deferred income taxes, net 54   (24 )
Other 25   (19 )
Net cash provided by operating activities 3,938   1,967  
     
Cash flows from investing activities    
Expenditures for property, plant, and equipment (3,265 ) (2,738 )
Purchases of available-for-sale securities (528 ) (1,002 )
Proceeds from sale of Lehi, Utah fab 893   —  
Proceeds from maturities of available-for-sale securities 313   216  
Proceeds from sales of available-for-sale securities 124   45  
Proceeds from government incentives 55   40  
Other (77 ) 21  
Net cash provided by (used for) investing activities (2,485 ) (3,418 )
     
Cash flows from financing activities    
Repayments of debt (1,949 ) (84 )
Repurchases of common stock – repurchase program (259 ) —  
Payments of dividends to shareholders (112 ) —  
Repurchases of common stock – withholdings on employee equity awards (102 ) (57 )
Payments on equipment purchase contracts (78 ) (97 )
Proceeds from issuance of debt 2,000   —  
Other (13 ) 24  
Net cash provided by (used for) financing activities (513 ) (214 )
     
Effect of changes in currency exchange rates on cash, cash equivalents, and restricted cash (6 ) 27  
     
Net increase (decrease) in cash, cash equivalents, and restricted cash 934   (1,638 )
Cash, cash equivalents, and restricted cash at beginning of period 7,829   7,690  
Cash, cash equivalents, and restricted cash at end of period $ 8,763   $ 6,052  
 
 

MICRON TECHNOLOGY, INC.
NOTES
(Unaudited)

Lehi, Utah Fab and 3D XPoint

In the second quarter of 2021, we updated our portfolio strategy to further strengthen our focus on memory and storage innovations for the data center market. In connection therewith, we determined that there was insufficient market validation to justify the ongoing investments required to commercialize 3D XPoint at scale. Accordingly, we ceased development of 3D XPoint technology and engaged in discussions with potential buyers for the sale of our facility located in Lehi that was dedicated to 3D XPoint production. As a result, we classified the property, plant, and equipment as held for sale and ceased depreciating the assets. On June 30, 2021, we announced a definitive agreement to sell our Lehi facility to Texas Instruments Incorporated (“TI”) and closed the sale on October 22, 2021.

In the first quarter of 2022, we received $893 million from TI for the sale of the Lehi facility and disposed of $918 million of net assets, consisting primarily of property, plant, and equipment of $921 million; $55 million of other assets, consisting primarily of a receivable for reimbursement of property taxes, equipment spare parts, and raw materials; and $58 million of liabilities, consisting primarily of a finance lease obligation. As a result of the disposition of the Lehi facility, we recognized a loss of $23 million included in restructure and asset impairments in the first quarter of 2022.

In the third quarter of 2021, we recognized a charge of $435 million included in restructure and asset impairments in connection with the definitive agreement with TI (and a tax benefit of $104 million included in income tax (provision) benefit) to write down the assets held for sale to the expected consideration, net of estimated selling costs. In the second quarter of 2021, we also recognized a charge of $49 million in cost of goods sold to write down 3D XPoint inventory in connection with our decision to cease further development of this technology.

Debt Activity

On November 1, 2021, we issued in a public offering $1.00 billion in principal amount of 2.703% senior notes due 2032 (green bonds), $500 million in principal amount of 3.366% senior notes due 2041, and $500 million in principal amount of 3.477% senior notes due 2051, and received aggregate net proceeds of $1.99 billion.

On November 17, 2021, we redeemed $1.25 billion in principal amount of our 2.497% senior notes due 2023 and $600 million in principal amount of our 4.640% senior notes due 2024 for $1.93 billion in cash and recognized a non-operating loss of $83 million.

 
MICRON TECHNOLOGY, INC.
RECONCILIATION OF GAAP TO NON-GAAP MEASURES
(In millions, except per share amounts)
 
  1st Qtr. 4th Qtr. 1st Qtr.
  December 2,
2021		 September 2,
2021		 December 3,
2020
       
GAAP gross margin $ 3,565   $ 3,912   $ 1,736  
Stock-based compensation 43   43   41  
Other 8   9   7  
Non-GAAP gross margin $ 3,616   $ 3,964   $ 1,784  
       
GAAP operating expenses $ 934   $ 957   $ 870  
Stock-based compensation (73 ) (50 ) (51 )
Restructure and asset impairments (38 ) (22 ) (8 )
Other 68   6   —  
Non-GAAP operating expenses $ 891   $ 891   $ 811  
       
GAAP operating income $ 2,631   $ 2,955   $ 866  
Stock-based compensation 116   93   92  
Restructure and asset impairments 38   22   8  
Other (60 ) 3   7  
Non-GAAP operating income $ 2,725   $ 3,073   $ 973  
       
GAAP net income $ 2,306   $ 2,720   $ 803  
Stock-based compensation 116   93   92  
Restructure and asset impairments 38   22   8  
Amortization of debt discount and other costs 9   8   7  
(Gain) loss on debt repurchases and conversions 83   —   —  
Other (60 ) 3   7  
Estimated tax effects of above and other tax adjustments (21 ) (68 ) (20 )
Non-GAAP net income $ 2,471   $ 2,778   $ 897  
       
GAAP weighted-average common shares outstanding – Diluted 1,130   1,138   1,135  
Adjustment for stock-based compensation 11   9   11  
Non-GAAP weighted-average common shares outstanding – Diluted 1,141   1,147   1,146  
       
GAAP diluted earnings per share $ 2.04   $ 2.39   $ 0.71  
Effects of the above adjustments 0.12   0.03   0.07  
Non-GAAP diluted earnings per share $ 2.16   $ 2.42   $ 0.78  
 
 

RECONCILIATION OF GAAP TO NON-GAAP MEASURES, Continued

  1st Qtr. 4th Qtr. 1st Qtr.
  December 2,
2021		 September 2,
2021		 December 3,
2020
       
GAAP net cash provided by operating activities $ 3,938   $ 3,884   $ 1,967  
       
Expenditures for property, plant, and equipment (3,265 ) (2,015 ) (2,738 )
Proceeds from sales of property, plant, and equipment 21   4   12  
Payments on equipment purchase contracts (78 ) (156 ) (97 )
Amounts funded by partners 55   160   40  
Investments in capital expenditures, net (3,267 ) (2,007 ) (2,783 )
Adjusted free cash flow $ 671   $ 1,877   $ (816 )
As of December 2,
2021		 September 2,
2021
     
Cash and short-term investments $ 9,580     $ 8,633    
Current and noncurrent restricted cash 83     66    
Long-term marketable investments 1,817     1,765    
Current and long-term debt (7,022 )   (6,776 )  
Net cash $ 4,458     $ 3,688    

The tables above reconcile GAAP to non-GAAP measures of gross margin, operating expenses, operating income, net income, diluted shares, diluted earnings per share, adjusted free cash flow, and net cash. The non-GAAP adjustments above may or may not be infrequent or nonrecurring in nature, but are a result of periodic or non-core operating activities. We believe this non-GAAP information is helpful in understanding trends and in analyzing our operating results and earnings. We are providing this information to investors to assist in performing analysis of our operating results. When evaluating performance and making decisions on how to allocate our resources, management uses this non-GAAP information and believes investors should have access to similar data when making their investment decisions. We believe these non-GAAP financial measures increase transparency by providing investors with useful supplemental information about the financial performance of our business, enabling enhanced comparison of our operating results between periods and with peer companies. The presentation of these adjusted amounts varies from amounts presented in accordance with U.S. GAAP and therefore may not be comparable to amounts reported by other companies. Our management excludes the following items in analyzing our operating results and understanding trends in our earnings:

  • Stock-based compensation;
  • Flow-through of business acquisition-related inventory adjustments;
  • Acquisition-related costs;
  • Employee severance;
  • Gains and losses from settlements and patent license charges;
  • Restructure and asset impairments;
  • Amortization of debt discount and other costs;
  • Gains and losses from debt repurchases and conversions;
  • Gains and losses from business acquisition activities;
  • Initial impact of inventory accounting policy change to FIFO and change in inventory cost absorption in the second quarter of 2021; and
  • The estimated tax effects of above, non-cash changes in net deferred income taxes, assessments of tax exposures, certain tax matters related to prior fiscal periods, and significant changes in tax law.

Non-GAAP diluted shares are adjusted for the impact of additional shares resulting from the exclusion of stock-based compensation from non-GAAP income.

MICRON TECHNOLOGY, INC.
RECONCILIATION OF GAAP TO NON-GAAP OUTLOOK

FQ2-22  GAAP Outlook   Adjustments   Non-GAAP Outlook
                
Revenue $7.5 billion ± $200 million    —       $7.5 billion ± $200 million
Gross margin 45.0% ± 1%    1%   A   46.0% ± 1%
Operating expenses $1,058 million ± $25 million   $83 million   B   $975 million ± $25 million
Diluted earnings per share(1) $1.83 ± $0.10   $0.12    A, B, C   $1.95 ± $0.10
Non-GAAP Adjustments
(in millions)		  
         
A Stock-based compensation – cost of goods sold $ 48  
A Other – cost of goods sold 5  
B Stock-based compensation – research and development 48  
B Stock-based compensation – sales, general, and administrative 35  
C Tax effects of the above items and other tax adjustments (2 )
        $ 134  

(1)   GAAP earnings per share based on approximately 1.13 billion diluted shares and non-GAAP earnings per share based on approximately 1.14 billion diluted shares.

The tables above reconcile our GAAP to non-GAAP guidance based on the current outlook. The guidance does not incorporate the impact of any potential business combinations, divestitures, restructuring activities, balance sheet valuation adjustments, strategic investments, financing transactions, and other significant transactions. The timing and impact of such items are dependent on future events that may be uncertain or outside of our control.

Related Topics:

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Continue Reading

Artificial Intelligence

Clinical Trials Matching Software Market Projected to Reach $832.56 million by 2030 – Exclusive Report by 360iResearch

Published

2 hours ago

on

April 19, 2024

By

clinical-trials-matching-software-market-projected-to-reach-$832.56-million-by-2030-–-exclusive-report-by-360iresearch

PUNE, India, April 18, 2024 /PRNewswire/ — The report titled “Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use – Global Forecast 2024-2030” is now available on 360iResearch.com’s offering, presents an analysis indicating that the market projected to grow from a size of $342.20 million in 2023 to reach $832.56 million by 2030, at a CAGR of 13.54% over the forecast period.

“The Global Surge in Adoption of Matching Software for Enhanced Participant Enrollment”
Clinical trials matching software stands at the forefront of revolutionizing clinical research by automating the process of identifying and enrolling eligible participants. These platforms offer a streamlined approach to match patient health profiles with trial requirements, accelerating enrollment and supporting the shift toward personalized healthcare using these advanced AI and ML technologies. Although integrating these systems poses challenges due to variations in healthcare IT infrastructure and the imperative for rigorous data security, the potential for market growth is substantial. In the Americas, a robust clinical trials ecosystem thrives; in the European Union, it has unified regulatory standards and extended to emerging regions such as the Middle East, Africa, and the APAC countries; the demand for such innovative solutions is on a steep rise. This demand is fueled by governmental support, the evolving regulatory landscape, and strategic partnerships to embed these solutions within electronic health records, underscoring a global movement toward optimizing clinical trial processes to better cater to specific patient demographics.
Download Sample Report @ https://www.360iresearch.com/library/intelligence/clinical-trials-matching-software
“The Rise of Virtual Trials and Advanced Matching Software”
The healthcare landscape is witnessing a transformative shift toward virtual clinical trials, fueled by technological advancements and the necessity for continuity during the COVID-19 pandemic. This transition supports research amid social distancing measures and introduces significant cost savings by reducing the need for physical infrastructure and in-person interactions. The efficiencies brought by electronic health records (EHR), wearable technologies, and automation streamline the entire process, from patient recruitment to data analysis. Several approaches, endorsed by regulatory bodies such as the FDA, represent a leap forward in making clinical trials more accessible and streamlined, ensuring that more patients can participate in potentially life-saving research without the geographical and logistic constraints of traditional trials.
“Enhancing Clinical Trials through Advanced Analytics, Rigorous Compliance, and Precision-Patient Matching”
Integrating advanced analytics, meticulous compliance monitoring, and precision-patient matching marks a significant advancement toward maximizing efficiency and fostering trial diversity. The software delivers insightful data on trial progress, participant demographics, and enrollment figures, empowering stakeholders to make well-informed decisions and optimize resource distribution to meet trial goals effectively by implementing cutting-edge analytics. The built-in compliance feature ensures trials are conducted in strict adherence to regulatory standards, minimizing risks associated with non-compliance. Furthermore, a robust data management system guarantees the integrity and availability of clinical trial data, which is critical for the seamless operation and real-time analysis of trials. The software includes state-of-the-art patient matching technology, which employs sophisticated algorithms and artificial intelligence to expedite recruitment by accurately identifying candidates who match specific trial requirements. This innovative approach accelerates the recruitment timeline and enhances the diversification of trial participants, paving the way for more inclusive and representative clinical research outcomes.
Request Analyst Support @ https://www.360iresearch.com/library/intelligence/clinical-trials-matching-software
“Medidata by Dassault Systèmes SE at the Forefront of Clinical Trials Matching Software Market with a Strong 11.30% Market Share”
The key players in the Clinical Trials Matching Software Market include International Business Machines Corporation, Science 37, Inc. by eMed, LLC, Medidata by Dassault Systèmes SE, AutoCruitment LLC, Deep 6 AI Inc., and others. These prominent players focus on strategies such as expansions, acquisitions, joint ventures, and developing new products to strengthen their market positions.
“Introducing ThinkMi: Revolutionizing Market Intelligence with AI-Powered Insights for the Clinical Trials Matching Software Market”
We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Clinical Trials Matching Software Market. ThinkMi stands out as your premier market intelligence partner, delivering unparalleled insights with the power of artificial intelligence. Whether deciphering market trends or offering actionable intelligence, ThinkMi is engineered to provide precise, relevant answers to your most critical business questions. This revolutionary tool is more than just an information source; it’s a strategic asset that empowers your decision-making with up-to-the-minute data, ensuring you stay ahead in the fiercely competitive Clinical Trials Matching Software Market. Embrace the future of market analysis with ThinkMi, where informed decisions lead to remarkable growth.
Ask Question to ThinkMi @ https://app.360iresearch.com/library/intelligence/clinical-trials-matching-software
“Dive into the Clinical Trials Matching Software Market Landscape: Explore 190 Pages of Insights, 286 Tables, and 22 Figures”
PrefaceResearch MethodologyExecutive SummaryMarket OverviewMarket InsightsClinical Trials Matching Software Market, by FunctionalityClinical Trials Matching Software Market, by DeploymentClinical Trials Matching Software Market, by End-UseAmericas Clinical Trials Matching Software MarketAsia-Pacific Clinical Trials Matching Software MarketEurope, Middle East & Africa Clinical Trials Matching Software MarketCompetitive LandscapeCompetitive PortfolioInquire Before Buying @ https://www.360iresearch.com/library/intelligence/clinical-trials-matching-software
Related Reports:
Clinical Trial Support Services Market – Global Forecast 2024-2030Virtual Clinical Trials Market – Global Forecast 2024-2030Clinical Trials Management System Market – Global Forecast 2024-2030About 360iResearch
Founded in 2017, 360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.
We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset — our people.
Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.
Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.
Contact 360iResearchMr. Ketan Rohom360iResearch Private Limited,Office No. 519, Nyati Empress,Opposite Phoenix Market City,Vimannagar, Pune, Maharashtra,India – 411014.Email: [email protected]: +1-530-264-8485India: +91-922-607-7550
To learn more, visit 360iresearch.com or follow us on LinkedIn, Twitter, and Facebook.
Logo – https://mma.prnewswire.com/media/2359256/360iResearch_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/clinical-trials-matching-software-market-projected-to-reach-832-56-million-by-2030—exclusive-report-by-360iresearch-302119709.html

Continue Reading

Artificial Intelligence

RepTrak Announces 2024 Global RepTrak® 100 Report

Published

10 hours ago

on

April 18, 2024

By

reptrak-announces-2024-global-reptrak-100-report

BOSTON, April 18, 2024 /PRNewswire/ — The RepTrak™ Company, the world’s leading reputation data and insights company, released its annual Global RepTrak 100 report. Utilizing its advanced reputation monitoring software, RepTrak gathered data from more than 243,000 survey responses across 14 major economies to rank the world’s 100 most reputable companies. They share that ranking alongside a full analysis of global corporate reputation trends and corresponding public sentiment in the 2024 report.

After two years of consecutive Reputation Score declines, this year’s Score is back up with an increase from 73.2 in 2023 to 73.8 in 2024. It’s a small increase after 2023’s full one-point drop. However, it’s an encouraging sign that companies have begun to recover from reputation falls driven by many challenges: macroeconomic issues, workplace difficulties, product problems, and corporate responsibility skepticism.
“This year’s report underscores a pivotal shift in the corporate landscape, spotlighting the remarkable adaptability and dedication of the Top 100 companies in responding to the dynamic needs of stakeholders,” states RepTrak CEO Mark Sonders. “The companies featured in our report are not just riding the wave of change; they are the ones steering it, proving that the best approach to business is one that embraces evolution and champions progress.”
RepTrak’s report explores how people thought, felt, and acted toward companies over the past year. Findings include notable increases in Conduct and Citizenship efforts, stakeholders’ rising willingness to invest, culturally resonant brand communications, and ESG Scores that soared despite skepticism around the acronym.
To read the full 2024 Global RepTrak 100 report, please visit: www.reptrak.com/globalreptrak
About RepTrak
The RepTrak™ Company is the world’s leading reputation data and insights company. We help companies by organizing and grading a variety of reputational elements, offering a real-world report card on their corporate reputation. Subscribers to the RepTrak program use our predictive insights to protect business value, improve return on investment, and increase their positive impact on society. RepTrak’s pairing of advanced metrics and dedicated reputation advisors offers clients an actionable analysis of their reputation data, aligning business objectives with stakeholder sentiment across different markets and sectors.
Established in 2004, The RepTrak Company owns the world’s largest reputation benchmarking database, gathering over 1 million company ratings per year used by CEOs, boards, and executives in more than 60 countries worldwide. For more information, please visit: www.reptrak.com
Logo – https://mma.prnewswire.com/media/2391550/RepTrak_Logo_Logo.jpg
Photo – https://mma.prnewswire.com/media/2391551/2024_GRT_Spreads__Instagram_Post.jpg

View original content:https://www.prnewswire.co.uk/news-releases/reptrak-announces-2024-global-reptrak-100-report-302121513.html

Continue Reading

Artificial Intelligence

Group-IB takes part in a global operation to cripple Canadian Phishing-as-a-Service provider LabHost

Published

12 hours ago

on

April 18, 2024

By

group-ib-takes-part-in-a-global-operation-to-cripple-canadian-phishing-as-a-service-provider-labhost

SINGAPORE, April 18, 2024 /PRNewswire/ — Group-IB, a leading cybersecurity company aimed at investigating, preventing, and fight digital crime announced today that it participated in a coordinated global takedown operation against prominent Canadian Phishing-as-a-Service (PhaaS) provider LabHost, which has led to the arrest of 37 suspects across the United Kingdom and around the world by law enforcement agencies. As part of the operation, Group-IB also conducted an extensive analysis of LabHost’s criminal history and infrastructure, including insights into LabHost’s administrative platform and the services it provides to its purported user base which exceeds 2,000 subscribers worldwide, who illegally obtained around 480,000 card numbers, 64,000 pin numbers, and over 1 million passwords from victims used for websites and other online services, according to law enforcement agencies.

“By leveraging our Threat Intelligence and Digital Risk Protection, we are able to identify and monitor phishing attacks and websites like those deployed by LabHost and its subscribers around the world, enabling us to actively alert and protect our customers, and in turn, their customers as well,” said Dmitry Volkov, Chief Executive Officer of Group-IB. “Today’s takedown operation demonstrates the agility and responsiveness of our decentralized Digital Crime Resistance Centers, and how quickly we can provide immediate and local assistance wherever our customers may be.”
First uncovered in late 2021, LabHost emerged as a fully automated Phishing-as-a-Service (PhaaS) platform, streamlining the creation of phishing websites meticulously mirroring the interface and functionality of prominent banking, postal, and financial entities, aimed at intercepting, seizing, and profiting from users’ personal, credit card, and online banking credentials. Users are prompted to select from various “membership plans,” tailored to target businesses and individuals in either the United States and Canada, or globally, akin to mobile subscription models. These plans encompass “standard,” “premium,” and “world membership” tiers, priced between US$179 and US$300 monthly, with options for monthly, quarterly, or annual billing cycles.
For media inquiries, please contact [email protected]
Photo – https://mma.prnewswire.com/media/2391017/Group_IB.jpgPhoto – https://mma.prnewswire.com/media/2391018/Group_IB_2.jpgLogo – https://mma.prnewswire.com/media/1853638/4657466/Group_IB_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/group-ib-takes-part-in-a-global-operation-to-cripple-canadian-phishing-as-a-service-provider-labhost-302121388.html

Continue Reading

Trending